Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN), an AI-driven pharmaceutical company focused on developing targeted cancer therapies, has scheduled its first quarter 2025 operating and financial results webcast for Thursday, May 15, 2025, at 9:00 a.m. ET. The company's CEO, Panna Sharma, along with other management team members, will discuss Q1 2025 results and provide updates on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. The webcast will be available for replay on the company's investor relations website after the call.

Lantern Pharma (NASDAQ: LTRN) reported its Q4 and full-year 2024 results, highlighting significant progress in its AI-driven oncology drug development programs. The HARMONIC™ trial for LP-300 showed an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with expansion in Japan and Taiwan. LP-184 received two FDA Fast Track Designations for Glioblastoma and Triple Negative Breast Cancer, plus three Rare Pediatric Disease Designations.

The company's RADR® AI platform surpassed 100 billion oncology-specific data points in 2024. Financial results showed cash position of $24.0 million as of December 31, 2024. Q4 net loss was $5.9 million ($0.54 per share), compared to $4.2 million ($0.39 per share) in Q4 2023. Full-year 2024 net loss per share was $1.93 versus $1.47 in 2023.

Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, has scheduled its fourth quarter and fiscal year 2024 financial results webcast for Thursday, March 27th, 2025, at 4:30 PM ET. The presentation will be led by President and CEO Panna Sharma, accompanied by the management team.

During the webcast, management will discuss:

• Q4 and full-year 2024 operating and financial results
• Upcoming milestones and clinical trials
• Development updates on the RADR® AI and machine learning platform

The company develops targeted cancer therapies using its proprietary RADR® AI platform and has multiple clinical-stage drug programs in development.

Lantern Pharma (NASDAQ: LTRN) announced the publication of its PCT patent application for a novel machine learning solution predicting blood-brain barrier (BBB) permeability. The technology has shown exceptional performance, processing up to 100,000 molecules per hour with industry-leading accuracy, with Lantern's AI algorithms holding five of the top eleven positions on the Therapeutic Data Commons Leaderboard.

The proprietary technology integrates advanced molecular representation techniques with synthetic data augmentation, processed by machine learning algorithms through Lantern's RADR® AI platform. The company's subsidiary, Starlight Therapeutics, plans to implement this technology for STAR-001 development. The PCT application allows Lantern to pursue worldwide patent protection for 20 years from filing, with expedited review initiated in the United States.

Lantern Pharma (NASDAQ: LTRN) has announced advancements in its RADR® AI platform for optimizing antibody-drug conjugate (ADC) development. The company's AI-driven approach has successfully identified 82 promising ADC targets and 290 target-indication combinations, while validating 729 potential payload molecules from over 50,000 compounds.

The research demonstrated that 22 targets have been clinically validated, while 60 novel targets present new intellectual property opportunities. The platform's payload molecules showed exceptional potency with GI50 values from picomolar to 10 nM ranges. According to the company, this AI-driven approach could reduce ADC development timelines by 30-50% and cut costs by up to 60% compared to traditional methods.

The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%. The company is advancing multiple ADC candidates through preclinical development, including a collaboration with the MAGICBULLET::Reloaded Initiative at the University of Bielefeld.